VERITY RESEARCHA LIBRARY OF POSSIBILITY

Small molecules.
Big questions.

FOLLOW YOUR CURIOSITY

Explore the science, the emerging ideas, and the conversations moving peptide research forward.

From the lab.
To a bigger conversation.

Original studies, scientific reviews, articles, and podcast conversations, organized around the possibilities being explored. Each source tells you what was studied—and where the idea comes from.

288 curated sources634 compounds explored

EXPLORE THE EVIDENCE

Your next rabbit hole.

THE RESEARCH LIBRARY / 01

Search the library

Filter by compound

Sort research

Prioritized for learning value, source quality and clarity, with a boost for newer research and less repeated coverage.

38 sources for “vb-rt”

Research paper

Retatrutide2024

Retatrutide reduces liver fat in a human substudy (opens in a new tab)

In 98 participants with fatty liver, retatrutide substantially reduced MRI-measured liver fat. The largest average relative reduction was 82.4% at 24 weeks.

Human research

Inside this research

Reductions tracked with improvements in abdominal fat and metabolic measures.

This measures liver fat, not biopsy-confirmed reversal of liver fibrosis; it is a substudy of the obesity trial.

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
Arun J. Sanyal et al. · Nature Medicine, 2024

Nature MedicineRead paper (opens in a new tab)

Research paper

Retatrutide2024

How one peptide engages three metabolic receptors (opens in a new tab)

Cryo-electron microscopy resolved retatrutide bound to GLP-1, GIP and glucagon receptors. Functional signaling and mutagenesis experiments helped explain shared and receptor-specific contacts.

Cell research

Inside this research

Conserved interactions and different extracellular-loop conformations help accommodate retatrutide at all three receptors.

Structural and cell-signaling experiments explain molecular engagement; they are not evidence of clinical comparative efficacy.

Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide
Wenzhuo Li et al. · Cell Discovery, 2024

Cell DiscoveryRead paper (opens in a new tab)

Scientific review

Retatrutide2025

What triple receptor agonism adds to obesity research (opens in a new tab)

This scientific review focuses on the rationale for triple agonists and the published retatrutide trial program. It considers metabolic endpoints, tolerability and unresolved clinical questions.

Mixed evidence

Inside this research

The review identifies glucagon-receptor activity as a mechanistic addition to combined GLP-1 and GIP signaling.

A narrative synthesis reuses earlier studies; comparisons across separate trials cannot establish superiority.

Triple Agonism Based Therapies for Obesity
Jonathan Goldney et al. · Current Cardiovascular Risk Reports, 2025

Current Cardiovascular Risk ReportsRead review (opens in a new tab)

Research paper

Retatrutide2023

Retatrutide produces substantial weight loss in a phase 2 trial (opens in a new tab)

In 338 adults, retatrutide produced substantial weight reduction over 48 weeks. The highest treatment group averaged 24.2% weight loss versus 2.1% with placebo.

Human research

Inside this research

The molecule activates GIP, GLP-1, and glucagon receptors.

Phase 2 trial; gastrointestinal events were common and heart rate increased during treatment.

Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Ania M. Jastreboff et al. · New England Journal of Medicine, 2023

New England Journal of MedicineRead paper (opens in a new tab)

Podcast episode

MOTS-C · Humanin · SS-312026

Mitochondrial peptides and human genetic variation (opens in a new tab)

Mitochondrial-peptide researcher Pinchas Cohen explains humanin discovery, MOTS-c biology and naturally occurring peptide variants. The interview discusses differences between preclinical experiments and limited human intervention data.

Commentary

Inside this episode

Cohen separates mitochondrial microproteins from fragments of larger proteins and discusses how natural sequence variants can affect biological activity.

Expert discussion is commentary; human genetic associations and mouse findings do not establish safety or efficacy of consumer injections. The transcript contains transcription and factual slips.

Mitochondria Peptides: MOTS-c, Humanin, Genetic Variation in Health & Disease | Pinchas Cohen | Episode 304
Nick Jikomes and Pinchas Cohen · Mind & Matter, 2026

Mind & MatterListen to episode (opens in a new tab)

Research paper

Retatrutide2026

Retatrutide in mouse and hamster MASH models (opens in a new tab)

A five-week preclinical study tested retatrutide in diet-induced obese mice and hamsters with liver disease. Researchers measured body composition, glucose metabolism, liver lipids and histology.

Animal research

Inside this research

Hepatic lipid content and metabolic measures improved, but effects on MASH histology and fibrosis were limited.

Short treatment in animal models cannot establish reversal of human liver fibrosis; lean mass also decreased in parts of the study.

Retatrutide Shows Multiple Metabolic Benefits in Diet‐Induced Obese MASH Mouse and Hamster Models
François Briand et al. · Obesity (Silver Spring, Md.), 2026

Obesity (Silver Spring, Md.)Read paper (opens in a new tab)

Research paper

Retatrutide2026

Retatrutide in mice lacking the MC4R pathway (opens in a new tab)

Investigators compared semaglutide, tirzepatide and retatrutide over 21 days in MC4R-knockout mice. They measured food intake, body composition, energy expenditure and metabolic markers.

Animal research

Inside this research

All three agents reduced body weight and both fat and lean mass despite MC4R deficiency.

Monogenic mouse obesity and experimental dosing do not establish efficacy or a drug ranking in people with MC4R variants.

Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison
Kosuke Hitaka et al. · International Journal of Obesity (2005), 2026

International Journal of Obesity (2005)Read paper (opens in a new tab)

Scientific review

Retatrutide2025

Retatrutide within the dual and triple agonist field (opens in a new tab)

This overview compares the preclinical and clinical development of gut-peptide co-agonists. Dedicated retatrutide sections describe phase 2 diabetes and obesity findings.

Mixed evidence

Inside this research

Adding glucagon to GLP-1/GIP agonism is discussed as a strategy to combine glycemic and energy-balance effects.

The review synthesizes heterogeneous agents and populations; its comparisons do not substitute for head-to-head trials.

Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data
Ioanna Α. Anastasiou et al. · Current Obesity Reports, 2025

Current Obesity ReportsRead review (opens in a new tab)

Science article

BPC-157 · Retatrutide2026

Peptide research beyond the wellness headlines (opens in a new tab)

Stanford researchers Katrin Svensson and Jonathan Long explain peptide signaling, the limits of gray-market claims and the distinction between drug development and consumer use. Retatrutide appears in the future-treatment discussion.

Commentary

Inside this perspective

The article separates clinical testing of specific drug candidates from untested online peptide use and discusses uncertainty about BPC-157’s claimed natural origin.

Institutional expert commentary is not an independent efficacy study, and regulatory descriptions reflect publication time.

Peptides talk is everywhere: But what does the science say?
Rachel Tompa · Stanford Medicine, 2026

Stanford MedicineRead article (opens in a new tab)

Research paper

Retatrutide2025

Retatrutide alters alcohol discrimination in rats (opens in a new tab)

Male and female rats trained in an alcohol-discrimination task received semaglutide, tirzepatide or retatrutide. The task assesses internal drug cues rather than real-world drinking outcomes.

Animal research

Inside this research

Acute retatrutide attenuated alcohol discrimination, as did the other two agents tested.

The retatrutide experiment was acute and preclinical; it does not establish treatment efficacy for alcohol use disorder.

Semaglutide, tirzepatide, and retatrutide attenuate the interoceptive effects of alcohol in male and female rats
McKinley Windram et al. · Psychopharmacology, 2025

PsychopharmacologyRead paper (opens in a new tab)

Community perspective

Retatrutide · Tirzepatide2026

Why the next metabolic drugs combine hormone signals (opens in a new tab)

Carrie MacMillan asks Yale obesity specialists why combining hormone signals may improve metabolic treatment. Retatrutide illustrates the move beyond two receptors, while muscle, bone, and tolerability shape the questions researchers ask next.

Commentary

Inside this perspective

The article explains why adding glucagon differs from simply increasing GLP-1 signaling.

An institutional explainer featuring clinician interpretation; it does not provide a head-to-head trial of every therapy discussed.

Beyond GLP-1s: Combination Therapy, New Hormones Reshape Obesity Treatment
Carrie MacMillan · Yale Medicine, 2026

Yale MedicineRead article (opens in a new tab)

Research paper

Retatrutide2025

Tumor progression after retatrutide-induced weight loss in mice (opens in a new tab)

Researchers tested retatrutide-induced weight loss in diet-induced obese mice bearing pancreatic or lung cancer models. They also examined immune changes and withdrawal of treatment.

Animal research

Inside this research

Retatrutide-treated mice showed reduced tumor engraftment and progression, with some tumor effects persisting after withdrawal and weight regain.

Mouse tumor-transplant models and incompletely separated weight-loss mechanisms cannot establish human cancer prevention or treatment.

Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression
Sandesh J Marathe et al. · npj Metabolic Health and Disease, 2025

npj Metabolic Health and DiseaseRead paper (opens in a new tab)

Showing 12 of 38 sources

Opening the research library…

A NOTE ON READING RESEARCH

Stay curious.
Read the source.

Categories describe areas of research and proposed benefits. A result in cells or animals is a starting point for exploration; it does not establish the same effect in people.

Articles, podcasts, and community perspectives capture ideas and experiences from the wider conversation. Their claims remain attributed to their authors. Open any source to explore its methods, context, and conclusions.

Small molecules.Big questions.

Your next rabbit hole.

Stay curious.Read the source.

Your next rabbit hole.

Small molecules.
Big questions.

Stay curious.
Read the source.